Indevus Pharmaceuticals Announces Completion Of Enrollment In Phase III Trial Of PRO 2000

�Indevus
Pharmaceuticals, Inc. (Nasdaq: IDEV) proclaimed the mop up of
registration in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the
Company's candidate vaginal microbicide for the prevention of HIV and other
sexually transmissible infections. The trial is sponsored by the United
Kingdom's Medical Research Council (MRC) and conducted by the Microbicides
Development Programme (MDP), an international partnership of researchers
established to develop microbicides for the prevention of HIV contagion.
This trial enrolled 9,395 women at clinics in South Africa, Tanzania,
Uganda, and Zambia. Results from this trial ar expected to be uncommitted by
the end of 2009.



This is the second heavy trial testing the safety and strength of
the 0.5% dose of PRO 2000 and the largest test of whatever microbicide to date.
In July 2007, enrollment of 3,century women was completed in Protocol HPTN 035
sponsored by the National Institute of Allergy and Infectious Diseases
(NIAID), part of the National Institutes of Health (NIH). Results from the
HPTN 035 visitation are expected to be available by early 2009.



"The completion of enrolment in this trial simon Marks a significant
milestone for Indevus, our shareholders and for women who may benefit from
a product that provides a female-controlled option for HIV and STD
bar," said Glenn L. Cooper, M.D., chair and headman executive
officer of Indevus. "We take now completed enrollment in two pivotal trials
with over 12,000 women participating. If the trials are successful, we
expect to be in a position to file marketing applications with regulatory
regime, including a New Drug Application with the U.S. Food and Drug
Administration, in 2010."



MDP 301 is a multi-national, randomized, double-blind,
placebo-controlled Phase III trial designed to examine the safety and
effectiveness of PRO 2000 in preventing HIV infection in women. The trial
will also tax effects on other sexually transmitted infections including
herpes virus, chlamydia and gonorrhea. All participants receive condoms and
risk-reduction counsel. The trial opened in October 2005, and is
currently underway at clinical centers in South Africa, Tanzania, Uganda
and Zambia. Completion of the trial is expected in the summer of 2009.



HPTN 035 is a transnational, randomized, placebo-controlled trial
designed to study the safety and effectivity of PRO 2000 and another
nominee vaginal microbicide in preventing HIV infection in women. This
run will besides assess personal effects on early sexually transmitted infections
including herpes, chlamydia and clap. The 0.5% dose of PRO 2000 is
being well-tried in comparison with a placebo and no treatment. All
participants receive condoms and risk-reduction counseling. The trial
involves seven clinical centers in South Africa, Malawi, Zimbabwe, Zambia,
and the United States. The trial opened in February 2005, and 3,hundred healthy
women were enrolled before aforethought recruitment complete in July 2007.
Completion of the HPTN 035 trial is expected later this year. Results from
the trial are expected by early 2009.

About Indevus



Indevus Pharmaceuticals, Inc. is a metier pharmaceutical company
engaged in the learning, development and commercialization of products
to treat atmospheric condition in urogenital medicine and endocrinology. The Company's approved
products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder,
VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central
precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The
Indevus development pipeline contains multiple compounds within the
Company's core therapeutic areas in addition to several partnered or
partnerable programs. The most advanced compounds in exploitation include,
VALSTAR(TM) for bladder cancer, NEBIDO(R) for male person hypogonadism, PRO 2000
for the prevention of infection by HIV and other sexually-transmitted
pathogens, and the octreotide imbed for acromegaly.

About MDP



The Microbicides Development Programme (MDP) is an Afro-European
partnership to develop vaginal microbicides for the prevention of HIV
transmission. MDP is coordinated jointly by Imperial College, London, and
the Clinical Trials Unit of the UK Medical Research Council. Partner
institutions in Africa ar University Teaching Hospital, Lusaka, Zambia;
Medical Research Council Uganda Virus Research Institute, Entebbe; African
Medical and Research Foundation and National Institute for Medical
Research, Mwanza, Tanzania; the Africa Centre for Health and Population
Studies, KwaZulu Natal, South Africa; South African Medical Research
Council, Durban; and the Reproductive Health and HIV Research Unit,
Department of Obstetrics and Gynaecology, University of Witwatersrand,
Johannesburg, South Africa. In Mozambique, there are two new MDP sites at
the rural Manhica Health Research Centre and at Mavalane Hospital in the
urban capital of Maputo. European partners include the London School of
Hygiene and Tropical Medicine, St. George's Hospital, London, and the
Universities of York, Southampton and Barcelona. Clinical sites ar located
in South Africa, Tanzania, Uganda, Zambia and Mozambique.



MDP has reinforced a vigorous multicultural and multidisciplinary research
network ready to undertake future work of like importance and
complexity. Years of working collegially have built coherency,
efficiency and mutual trust among the scientists, clinical staff, information
managers, and other professionals and support staff comprising this
Afro-European and pan-African clinical test network, as well as sound
relationships with surrounding communities. MDP has likewise achieved
significant improvements in African laboratory capacity and other research
infrastructure, as well as upgrading and reinforcement of professional
capacity at its African research sites.

About PRO 2000



PRO 2000 (naphthalene sulfonate polymer) is a topical vaginal
microbicide under development to prevent the intimate transmission of HIV and
other sexually transmitted diseases.

Forward Looking Statements



Except for the descriptions of historical facts contained herein, this
press acquittance contains advanced statements that involve risks and
uncertainties that could cause the Company's actual results and financial
precondition to dissent materially from those awaited by the
forward-looking statements. These risks and uncertainties are go down forth in
the Company's filings under the Securities Act of 1933 and the Securities
Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, merely
are not limited to: dependence on the success of SANCTURA, SANCTURA XR,
NEBIDO, VANTAS and SUPPRELIN LA; indigence for additional funds and corporate
partners, including for the development of our products; potency of
our sales force; competition and its effect on pricing, spending,
third party relationships and revenues; dependence on third gear parties for
supplies, peculiarly for histrelin, manufacturing, marketing, and
clinical trials; risks ated with being a manufacturer of some of our
products; risks associated with contractual agreements, especially for
the manufacture and co-promotion of SANCTURA and SANCTURA XR and the
manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on
intellectual dimension and having limited patents and proprietorship rights;
dependency on market exclusivity, changes in reimbursement policies and/or
rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any
future products; espousal by the healthcare residential district of our approved
products and mathematical product candidates; uncertainties relating to clinical trials,
regulatory approval and commercialization of our products, specially
SANCTURA XR, NEBIDO, and VALSTAR; ware liability and insurance
uncertainties; risks relating to the Redux-related litigation; history of
operating losings and expectation of succeeding losses; uncertainties relating
to controls over financial reporting; valuation of our Common Stock; risks
related to repayment of debts; risks related to increased leverage; general
worldwide economic conditions and related uncertainties; and other risks.
Indevus undertakes no obligation to publicly update any forward-looking
statement, whether as a consequence of young information, future events or
otherwise.


Indevus Pharmaceuticals, Inc.
http://www.indevus.com



View drug information on Sanctura; Supprelin LA; Valstar.



More info

• Back pain eased by good posture
• Trace arsenic levels in water linked to diabetes
• Hospital death rates unveiled for first-time comparison
• Dogs can sniff right from wrong
• Spot a liar with his ‘blinking’

Greater Specificity Of Cardiac Risk Tests With The Randox HDL And LDL Clearance Method

�With the revolutionary Randox HDL and LDL clearance method, division of the lipid profile, specificity of testing and accuracy of diagnosis is vastly improved. This has replaced traditional assessment of cardiovascular disease (CVD) peril which oftentimes provided inaccurate and insufficient information for the clinician, possibly in the lead to misdiagnosis of the patient.


The lipid profile, a group of tests performed to determine risk of exposure of CVD, comprises tally cholesterol, triglycerides, high denseness lipoproteins (HDL) and humiliated density lipoproteins (LDL) cholesterol and extra parameters such as apolipoproteins. LDL cholesterin transports cholesterin to the cells for utilisation and plays a central role in the development of atherosclerotic lesions. It is generally regarded as the most important risk factor for CVD. HDL cholesterol, a damaging risk constituent, transports cholesterol from the cells to the liver for metamorphosis and riddance from the body. Regular assessment of these parameters is necessary to instal risk and, if necessary, monitor handling.


Traditional LDL cholesterol measurement based on the Friedewald equation deliberate from three separate assays, requires a fasting affected role sample and inaccurately estimates cholesterol in hypertriglyceridaemia resulting in misclassification of up to 50% of patient samples. Direct masking methods are a recent development in HDL cholesterol analysis in which non-HDL molecules are masked initially and then HDL cholesterol is measured. However, these methods underestimate HDL levels in hypertriglyceridaemia. This is ascribable to the fact that in abnormal samples, the composition of the lipoproteins is altered by these high levels of triglycerides and consequently cannot be distinguished during the masking piece process. Furthermore, these methods show poor agreement with ultracentrifugation employed in gold standard reference laboratories.


The Randox HDL and LDL clearance methods overcome these issues by completely removing the non-HDL/LDL molecules before directly measuring the HDL/LDL cholesterol in the sampling. It is highly specific and therefore eliminates problems associated with hypertriglyceridaemia. The Randox HDL and LDL clearance methods show fantabulous correlation with ultracentrifugation highlight its superior accuracy.


Randox HDL and LDL clearance method kits are liquid, ready to use, automatable assays with a broad measuring range and good stability. Accurate HDL and LDL cholesterin measurement is vital to establish CVD risk, and to determine therapeutic personal effects. By victimisation Randox direct clearance methods you canful be assured of a more accurate diagnosis and confidence in your results.

About Randox


Randox is an international diagnostics company, headquartered in the UK. Randox develop, manufacture and market clinical symptomatic products worldwide. Core products are: Biochip Array Technology; clinical chemistry analysers and reagents; calibre controls and EQA; recombinant proteins and antibodies.

Randox Laboratories

Diamond Road

Crumlin

Co. Antrim BT29 4QY

United Kingdom
http://www.randox.com


More info

• Food ads target kids, FTC reports
• Crystal clue in army brain injury
• Brown recluse spider makes its venomous presence known
• Cell change ‘keeps organs young’
• Researchers develop vision test that can detect diabetes

Emmis Interactive Unveils Suite of Custom Products, Tools and Games

"Confidence Pool" guaranteed to lower productivity in every office

CHICAGO, Aug. 5 -- For the number one time, Emmis Interactive,
Inc., the software and consulting company that empowers the reinvention of
local media, today announced it is opening up its catalogue of custom
products, tools and games to radio broadcasters and former local media
companies to purchase a la carte du jour.

"Radio stations of the Cross, magazines and television stations now induce the
opportunity to